S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.16
$0.39
52-Week Range
N/A
Volume
1.27 million shs
Average Volume
160,047 shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Medicenna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$2.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.17) to ($0.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.02 out of 5 stars

Medical Sector

832nd out of 938 stocks

Pharmaceutical Preparations Industry

370th out of 417 stocks

MDNA stock logo

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

MDNA Stock News Headlines

Medicenna Therapeutics Corp MDNA
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Medicenna Announces Appointment of New Auditor
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Medicenna Therapeutics Names Humphrey Gardner CMO
The Latest Analyst Ratings for Medicenna Therapeutics
Medicenna Therapeutics's Earnings: A Preview
See More Headlines
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/29/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MDNA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.00
Low Stock Price Target
$2.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-7,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.32 per share

Miscellaneous

Free Float
46,587,000
Market Cap
$10.93 million
Optionable
Not Optionable
Beta
1.30
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Fahar Merchant Ph.D. (Age 66)
    Founder, Chairman, President & CEO
    Comp: $327.41k
  • Ms. Rosemina Merchant B.Sc. (Age 66)
    M.E.Sc, Founder & Chief Development Officer
    Comp: $262.62k
  • Mr. Jeff Caravella M.B.A.
    Chief Financial Officer
  • Mr. Brent Meadows M.B.A.
    Chief Business Officer
  • Dr. Humphrey A. R. Gardner FCAP
    M.D., Chief Medical Officer
  • Dr. Samuel R. Denmeade M.D.
    Scientific Advisor

MDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings
or view top-rated stocks.

What is Medicenna Therapeutics' stock price target for 2024?

2 brokerages have issued 1-year price objectives for Medicenna Therapeutics' stock. Their MDNA share price targets range from $2.50 to $3.00. On average, they expect the company's stock price to reach $2.75 in the next year.
View analysts price targets for MDNA
or view top-rated stocks among Wall Street analysts.

How were Medicenna Therapeutics' earnings last quarter?

Medicenna Therapeutics Corp. (NASDAQ:MDNA) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. During the same quarter in the previous year, the business posted ($0.06) EPS.

This page (NASDAQ:MDNA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners